SEARCH

SEARCH BY CITATION

References

  • 1
    Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29, 1518.
  • 2
    Adams RH & Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8, 464478.
  • 3
    Hanahan D & Winberg RA (2011) Hallmarks of cancer: the next generation. Cell 144, 646674.
  • 4
    Butler JM, Kobayashi H & Rafii S (2010) Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10, 138146.
  • 5
    Theocharis AD, Tzanakakis G & Karamanos NK (2010) Proteoglycans in health and disease: novel proteoglycan roles in malignancy and their pharmacological targeting. FEBS J 277, 39043923.
  • 6
    Karamanos NK & Tzanakakis GN (2012) Glycosaminoglycans: from ‘cellular glue’ to novel therapeutical agents. Curr Opin Pharmacol 12, 220222.
  • 7
    Sottile J (2004) Regulation of angiogenesis by extracellular matrix. Biochim Biophys Acta 1654, 1322.
  • 8
    Iozzo RV (2005) Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol 6, 646656.
  • 9
    Iozzo RV, Zoeller JJ & Nyström A (2009) Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis. Mol Cells 27, 503513.
  • 10
    Iozzo RV & Sanderson RD (2011) Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15, 10131031.
  • 11
    Neill T, Schaefer L & Iozzo RV (2012) Decorin, a guardian from the matrix. Am J Pathol 181, 380387.
  • 12
    Schaefer L & Iozzo RV (2008) Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem 283, 2130521309.
  • 13
    Vogel KG, Paulsson M & Heinegård D (1984) Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem J 223, 587597.
  • 14
    Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE & Iozzo RV (1997) Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 136, 729743.
  • 15
    Häkkinen L, Strassburger S, Kahari VM, Scott PG, Eichstetter I, Iozzo RV & Larjava H (2000) A role for decorin in the structural organization of periodontal ligament. Lab Invest 80, 18691880.
  • 16
    Kalamajski S & Oldberd Å (2010) The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol 29, 248253.
  • 17
    Robinson PS, Lin TW, Jawad AF, Iozzo RV & Soslowsky LJ (2004) Investigating tendon fascicle structure–function relationship in a transgenic age mouse model using multiple regression models. Ann Biomed Eng 32, 924931.
  • 18
    Robinson PS, Huang TF, Kazam E, Iozzo RV, Birk DE & Soslowsky LJ (2005) Influence of decorin and biglycan on mechanical properties of multiple tendons in knockout mice. J Biomech Eng 127, 181185.
  • 19
    Rühland C, Schönherr E, Robenek H, Hansen U, Iozzo RV, Bruckner P & Seidler DG (2007) The glycosaminoglycan chain of decorin plays an important role in collagen fibril formation at the early stages of fibrillogenesis. FEBS J 274, 42464255.
  • 20
    Reed CC & Iozzo RV (2002) The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J 19, 249255.
  • 21
    Adany R, Heimer R, Caterson B, Sorrell JM & Iozzo RV (1990) Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. J Biol Chem 265, 1138911396.
  • 22
    Iozzo RV (1988) Proteoglycans and neoplasia. Cancer Metastasis Rev 7, 3950.
  • 23
    Danielson KG, Fazzio A, Cohen I, Cannizzaro LA, Eichstetter I & Iozzo RV (1993) The human decorin gene: intron–exon organization, discovery of two alternatively spliced exons in the 5′ untranslated region, and mapping of the gene to chromosome 12q23. Genomics 15, 146160.
  • 24
    Santra M, Danielson KG & Iozzo RV (1994) Structural and functional characterization of the human decorin gene promoter. A homopurine–homopyrimidine S1 nuclease-sensitive region is involved in transcriptional control. J Biol Chem 269, 579587.
  • 25
    Mauviel A, Korang K, Santra M, Tewari D, Uitto J & Iozzo RV (1996) Identification of a bimodal regulatory element encompassing a canonical AP-1 binding site in the proximal promoter region of the human decorin gene. J Biol Chem 271, 2482424829.
  • 26
    Goldoni S, Owens RT, McQuillan DJ, Shriver Z, Sasisekharan R, Birk DE, Campbell S & Iozzo RV (2004) Biologically active decorin is a monomer in solution. J Biol Chem 279, 66066612.
  • 27
    Iozzo RV, Moscatello D, McQuillan DJ & Eichstetter I (1999) Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274, 44894492.
  • 28
    Santra M, Eichstetter I & Iozzo RV (2000) An anti-oncogenic role for decorin: downregulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem 275, 3515335161.
  • 29
    Santra M, Reed CC & Iozzo RV (2002) Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping with but distinct from the EGF-binding epitope. J Biol Chem 277, 3567135681.
  • 30
    Goldoni S & Iozzo RV (2008) Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123, 24732479.
  • 31
    Goldoni S, Humphries A, Nyström A, Sattar S, Owens RT, McQuillan DJ, Ireton K & Iozzo RV (2009) Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 185, 743754.
  • 32
    Schönherr E, Sunderkötter C, Iozzo RV & Schaefer L (2005) Decorin, a novel player in the insulin-like growth factor system. J Biol Chem 280, 1576715772.
  • 33
    Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, Sorokin L, Gröne H-J, Reinhardt DP, Pfeilschifter J, Iozzo RV, et al. (2007) Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-1 receptor and mammalian target of rapamycin. Am J Pathol 170, 301315.
  • 34
    Merline R, Lazaroski S, Babelova A, Tsalastra-Greul W, Pfeilschifter J, Schluter KD, Gunther A, Iozzo RV, Schaefer RM & Schaefer L (2009) Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J Physiol Pharmacol 60 (Suppl 4), 513.
  • 35
    Iozzo RV, Buraschi S, Genua M, Xu S-Q, Solomides CC, Peiper SC, Gomella LG, Owens RT & Morrione A (2011) Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem 286, 3471234721.
  • 36
    Csordás G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, Nugent MA, Hajnóczky G & Iozzo RV (2000) Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem 275, 3287932887.
  • 37
    Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, Owens RA, McQuillan DJ & Iozzo RV (2006) Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 281, 2640826418.
  • 38
    Schaefer L & Iozzo RV (2012) Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr Opin Genet Dev 22, 5657.
  • 39
    Reed CC, Gauldie J & Iozzo RV (2002) Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 21, 36883695.
  • 40
    Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, Owens RA, McQuillan DJ & Iozzo RV (2008) An anti-metastatic role for decorin in breast cancer. Am J Pathol 173, 844855.
  • 41
    Reed CC, Waterhouse A, Kirby S, Kay P, Owens RA, McQuillan DJ & Iozzo RV (2005) Decorin prevents metastatic spreading of breast cancer. Oncogene 24, 11041110.
  • 42
    Merline R, Moreth K, Beckmann J, Nastase MV, Zeng-Brouwers J, Tralhão JG, Lemarchand P, Pfeilschifter J, Schaefer RM, Iozzo RV, et al. (2011) Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and microRNA-21. Sci Signal 4, ra75, doi:10.1126/scisignal.2001868.
  • 43
    Seidler DG, Mohamed NA, Bocian C, Stadtmann A, Hermann S, Schäfers K, Schäfers M, Iozzo RV, Zarbock A & Götte M (2011) The role for decorin in delayed-type hypersensitivity. J Immunol 187, 61086199.
  • 44
    Moreth K, Iozzo RV & Schaefer L (2012) Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. Cell Cycle 11, 20842091.
  • 45
    Nikitovic D, Aggelidakis J, Young MF, Iozzo RV, Karamanos NK & Tzanakakis GN (2012) The biology of small leucine-rich proteoglycans in bone pathophysiology. J Biol Chem 287, 3392633933.
  • 46
    Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B & Eichstetter I (1999) Cooperative action of germline mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci USA 96, 30923097.
  • 47
    Bi X, Tong C, Dokendorff A, Banroft L, Gallagher L, Guzman-Hartman G, Iozzo RV, Augenlicht LH & Yang W (2008) Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis 29, 14351440.
  • 48
    Bi X, Pohl NM, Yang GR, Gou Y, Guzman G, Kajdacsy-Balla A, Iozzo RV & Yang W (2012) Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis 33, 326330.
  • 49
    Järveläinen H, Puolakkainen P, Pakkanen S, Brown EL, Höök M, Iozzo RV, Sage H & Wight TN (2006) A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen 14, 443452.
  • 50
    De Luca A, Santra M, Baldi A, Giordano A & Iozzo RV (1996) Decorin-induced growth suppression is associated with upregulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 271, 1896118965.
  • 51
    Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B & Iozzo RV (1997) Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 100, 149157.
  • 52
    Buraschi S, Pal N, Tyler-Rubinstein N, Owens RT, Neill T & Iozzo RV (2010) Decorin antagonizes Met receptor activity and downregulates β-catenin and Myc levels. J Biol Chem 285, 4207542085.
  • 53
    Iozzo RV & Schaefer L (2010) Proteoglycans in health and disease: novel regulatory signaling mechanisms induced by the small leucine-rich proteoglycans. FEBS J 277, 38643875.
  • 54
    Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, Polverini P & Rosen EM (1993) Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 90, 19371941.
  • 55
    Grant DS, Yenisey C, Rose RW, Tootell M, Santra M & Iozzo RV (2002) Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 21, 47654777.
  • 56
    Neill T, Painter H, Buraschi S, Owens RT, Lisanti MP, Schaefer L & Iozzo RV (2012) Decorin antagonizes the angiogenic network. Concurrent inhibition of Met, hypoxia inducible factor-1α and vascular endothelial growth factor A and induction of thrombospondin-1 and TIMP3. J Biol Chem 287, 54925506.
  • 57
    Murphy-Ullrich JE & Iozzo RV (2012) Thrombospondins in physiology and disease: new tricks for old dogs. Matrix Biol 31, 152154.
  • 58
    Mosher DF & Adams JC (2012) Adhesion-modulating/matricellular ECM protein families: a structural, functional and evolutionary appraisal. Matrix Biol 31, 155161.
  • 59
    Armstrong LC & Bornstein P (2003) Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 22, 6371.
  • 60
    Hosono Y, Yamaguchi T, Mizutani E, Yanagisawa K, Arima C, Tomida S, Shimada Y, Hiraoka M, Kato S, Yokoi K, et al. (2012) MYBPH, a transcriptional target of TTF-1, inhibits ROCK1, and reduces cell motility and metastasis. EMBO J 31, 481493.
  • 61
    Roberts DD, Miller TW, Rogers NM, Yao M & Isenberg JS (2012) The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47. Matrix Biol 31, 162169.
  • 62
    Risher WC & Eroglu C (2012) Thrombospondins as key regulators of synaptogenesis in the central nervous system. Matrix Biol 31, 170177.
  • 63
    Sweetwyne MT & Murphy-Ullrich JE (2012) Thrombospondin 1 in tissue repair and fibrosis: TGF-β-dependent and independent mechanisms. Matrix Biol 31, 178186.
  • 64
    Kyriakides TR & MacLauchlan S (2009) The role of thrombospondins in wound healing, ischemia, and the foreign body reaction. J Cell Commun Signal 3, 215225.
  • 65
    Kazerounian S, Yee KO & Lawler J (2008) Thrombospondins in cancer. Cell Mol Life Sci 65, 700712.
  • 66
    Zhang X, Kazerounian S, Duquette M, Peruzzi C, Nagy JA, Dvorak HF, Parangi S & Lawler J (2009) Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J 23, 33683376.
  • 67
    Adams JC & Lawler J (2011) The thrombospondins. Cold Spring Harb Perspect Biol 3, 129.
  • 68
    Kalas W, Yu JL, Milson C, Rosenfield J, Benezra R, Bornstein P & Rak J (2005) Oncogenes and angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant Ras. Cancer Res 65, 88788886.
  • 69
    Watnick RS, Cheng Y-N, Rangarajan A, Ince TA & Weinberg RA (2003) Ras modulates myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3, 219231.
  • 70
    Volpert O, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K & Alani RM (2002) Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2, 473483.
  • 71
    Swarbrick A, Åkerfeldt MC, Lee CSL, Sergio CM, Caldon CE, Hunter L-JK & Sutherland RL (2005) Regulation of cyclin expression and cell cycle progression in breast epithelial cells by helix–loop–helix protein Id1. Oncogene 24, 381389.
  • 72
    Majack RA, Mildbrandt J & Dixit VM (1987) Induction of thrombospondin messenger RNA levels occurs as an immediate primary response to platelet-derived growth factor. J Biol Chem 262, 88218825.
  • 73
    Berthou S, Aebersold DM, Schimdt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang S, Howlett AR, et al. (2004) The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23, 53875393.
  • 74
    Zhang Y-W, Su Y, Volpert OV & Vande Woude GF (2003) Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100, 1271812723.
  • 75
    Levitzki A & Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267, 17821788.
  • 76
    Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z & Koprowski H (1987) Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. Cancer Res 47, 36923696.
  • 77
    Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, Liu L, Jia D, Wu J, Ye Y, et al. (2011) MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res 17, 75747583.
  • 78
    Lee DH, Shi J, Jeoung NH, Kim MS, Zabolotny JM, Lee SW, White MF, Wei L & Kim B-K (2009) Targeted disruption of ROCK1 causes insulin resistance in vivo. J Biol Chem 284, 1177611780.
  • 79
    Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, Morii N, et al. (1996) The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 15, 18851893.
  • 80
    Aznar S & Lacal JC (2001) Rho signals to cell growth and apoptosis. Cancer Lett 165, 110.
  • 81
    Sahai E & Marxhall CJ (2002) RHO-GTPases and cancer. Nat Rev Cancer 21, 133142.
  • 82
    Fritz G, Brachetti C, Bahlmann F, Schmidt M & Kaina B (2002) Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 87, 635644.
  • 83
    Filipazzi P, Bürdek M, Villa A, Rivoltini L & Huber V (2012) Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol 22, 342349.
  • 84
    Henderson MC & Azorsa DO (2012) The genomic and proteomic content of cancer cell-derived exosomes. Front Oncol 2, 119.
  • 85
    Logozzi M, De Milito A, Lugini L, Borghi M, Calabrò L, Spada M, Perdicchio M, Marino ML, Federici C, Lessi E, et al. (2009) High levels of exosomes expressing CD36 and caveolin-1 in plasma of melanoma patients. PLoS One 4, e5219.
  • 86
    Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A & Kalluri R (2004) Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64, 15701574.
  • 87
    Hodges RR, Guilbert E, Shatos MA, Natarajan V & Dartt DA (2011) Phospholipase D1, but not D2, regulates protein secretion via Rho/ROCK in a Ras/Raf-independent, MEK-dependent manner in rat lacrimal gland. Invest Ophthalmol Vis Sci 52, 21992210.
  • 88
    Wong CCL, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, Fraley SI, Wong C-M, Khoo U-S, Ng IOL, et al. (2011) Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci USA 108, 1636916374.
  • 89
    Belletti B, Pellizzari I, Berton S, Fabris L, Wolf K, Lovat F, Schiappacassi M, D'Andrea S, Nicoloso MS, Lovisa S, et al. (2010) p27Kip1 controls cell morphology and motility by regulating microtubule-dependent lipid raft recycling. Mol Cell Biol 30, 22292240.
  • 90
    Xaus J, Comalada M, Cardó M, Valledor AF & Celada A (2001) Decorin inhibits macrophage colony-stimulating factor proliferation of macrophages and enhances cell survival through induction of p27Kip1 and p21Waf1. Blood 98, 21242133.
  • 91
    Buraschi S, Neill T, Owens RT, Iniguez LA, Purkins G, Vadigepalli R, Evans B, Schaefer L, Peiper SC, Wang Z, et al. (2012) Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft model. PLoS One 7, e45559.
  • 92
    Gonzalez EM, Reed CC, Bix G, Fu J, Zhang Y, Gopalakrishnan B, Greenspan DS & Iozzo RV (2005) BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J Biol Chem 280, 70807087.
  • 93
    Goyal A, Pal N, Concannon M, Paulk M, Doran M, Poluzzi C, Sekiguchi K, Whitelock JM, Neill T & Iozzo RV (2011) Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2). J Biol Chem 286, 2594725962.
  • 94
    Ryynänen M, Ryynänen J, Solberg S, Iozzo RV, Knowlton RG & Uitto J (1992) Genetic linkage of type VII collagen (COL7A1) to dominant dystrophic epidermolysis bullosa in families with abnormal anchoring fibrils. J Clin Invest 89, 974980.
  • 95
    Goyal A, Poluzzi C, Willis AC, Smythies J, Shellard A, Neill T & Iozzo RV (2012) Endorepellin affects angiogenesis by antagonizing diverse VEGFR2-induced signaling pathways: transcriptional repression of HIF-1α and VEGFA and concurrent inhibition of NFAT1 activation. J Biol Chem 287, 4354343556.
  • 96
    Lo Cicero A, Majkowska I, Nagase H, Di Liegro I & Troeberg L (2012) Microvesicles shed by oligodendroglioma cells and rheumatoid synovial fibroblasts contain aggrecanase activity. Matrix Biol 31, 229233.